Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GH
GH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GH News
RBC Capital Markets Initiates Guardant Health with Outperform Rating
Jun 12 2026
seekingalpha
Biotech Sector Sees Surge in FDA and Global Approvals
Jun 12 2026
NASDAQ.COM
Latest Ratings and Outlook from Wall Street
Jun 12 2026
CNBC
Guardant360 CDx Receives FDA Approval for Cancer Diagnosis
Jun 11 2026
NASDAQ.COM
Guardant360 CDx Receives FDA Approval as Companion Diagnostic
Jun 11 2026
NASDAQ.COM
FDA Approves Guardant360 CDx for HERNEXEOS Treatment
Jun 11 2026
Newsfilter
Grail: A Potential Sleeper Stock in Liquid Biopsies
Jun 08 2026
Fool
Grail's Multi-Cancer Early Detection Test Awaits FDA Approval
Jun 08 2026
NASDAQ.COM
Latest Ratings and Outlook from Wall Street
Jun 05 2026
CNBC
Latest Rating Changes on Wall Street
Jun 02 2026
CNBC
Q32 Bio Soars Over 85% on $55 Million Private Placement Announcement
May 28 2026
NASDAQ.COM
Biotech Sector Regulatory Approvals and Collaborations
May 22 2026
NASDAQ.COM
Guardant Health Receives FDA Approval for New Cancer Test
May 20 2026
seekingalpha
Guardant Health Receives FDA Approval for New Liquid Biopsy
May 20 2026
NASDAQ.COM
Guardant Health's New FDA-Approved Liquid Biopsy Enhances Cancer Testing
May 20 2026
Newsfilter
Guardant Health Grants RSUs to 267 New Employees
May 18 2026
Newsfilter
Show More News
